On Aug. 19, 2020, Quidel announced that labeling for Quidel’s Emergency Use Authorization (EUA) for the Sofiaﾮ SARS Antigen FIA had been amended to include either nasal or nasopharyngeal swabs.

The new kit labeling, with the addition of a nasopharyngeal swab, allows Quidel to offer a second kit configuration to support the nasopharyngeal sample commonly performed in hospitals and helps alleviate some of the supply chain constraints around nasal swab-based kits.